Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
2.
Melanoma Res ; 33(5): 425-430, 2023 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-37352544

RESUMEN

CDKN2A pathogenic variants are well known to be associated with cutaneous melanoma and noncutaneous tumors (NCTs). Herein, we investigated the temporal correlation between the first cutaneous melanoma and NCT both in CDKN2A mutation carriers (MUT) and in wild-type melanoma patients, a poorly explored issue to date. Two hundred forty-five cutaneous melanoma patients were genotyped for the CDKN2A gene and divided into 51 MUT and 189 wild-type; the remaining five variant carriers were excluded from the analyses. MUT developed a significantly higher number of cutaneous melanoma than wild-type, while 13.7% in both genotyped groups received a diagnosis of at least one malignant NCT, without statistically significant differences. The onset of the first cutaneous melanoma preceded that of the first malignant or benign NCT in both MUT and wild-type patients by an average of 4.5 and 3.02 years, respectively. Considering only malignant tumors, the diagnosis of melanoma preceded that of the first NCT on an average of 8 and 4.34 years, in MUT and wild-type patients respectively. We emphasize the relevance to adopt a global vision for the primary and secondary surveillance of patients affected by cutaneous melanoma, not only limited to high-risk for multiple primary skin cancers but also to NCT that may develop several years after the diagnosis of the first cutaneous melanoma.


Asunto(s)
Inhibidor p16 de la Quinasa Dependiente de Ciclina , Melanoma , Neoplasias Cutáneas , Humanos , Inhibidor p16 de la Quinasa Dependiente de Ciclina/genética , Genotipo , Melanoma/complicaciones , Melanoma/genética , Melanoma/patología , Neoplasias Cutáneas/complicaciones , Neoplasias Cutáneas/genética , Neoplasias Cutáneas/patología , Melanoma Cutáneo Maligno
6.
Medicina (Kaunas) ; 55(7)2019 Jul 07.
Artículo en Inglés | MEDLINE | ID: mdl-31284637

RESUMEN

Congenital sensorineural hearing loss may occur in association with inborn pigmentary defects of the iris, hair, and skin. These conditions, named auditory-pigmentary disorders (APDs), represent extremely heterogeneous hereditary diseases, including Waardenburg syndromes, oculocutaneous albinism, Tietz syndrome, and piebaldism. APDs are part of the neurocristopathies, a group of congenital multisystem disorders caused by an altered development of the neural crest cells, multipotent progenitors of a wide variety of different lineages, including those differentiating into peripheral nervous system glial cells and melanocytes. We report on clinical and genetic findings of two monozygotic twins from a large Albanian family who showed a complex phenotype featured by sensorineural congenital deafness, severe neuropsychiatric impairment, and inborn pigmentary defects of hair and skin. The genetic analyzes identified, in both probands, an unreported co-occurrence of a new heterozygous germline pathogenic variant (c.2484 + 5G > T splicing mutation) in the KIT gene, consistent with the diagnosis of piebaldism, and a heterozygous deletion at chromosome 15q13.3, responsible for the neuropsychiatric impairment. This case represents the first worldwide report of dual locus inherited syndrome in piebald patients affected by a complex auditory-pigmentary multisystem phenotype. Here we also synthesize the clinical and genetic findings of all known neurocristopathies characterized by a hypopigmentary congenital disorder.


Asunto(s)
Pérdida Auditiva Sensorineural/genética , Piebaldismo/genética , Femenino , Pérdida Auditiva Sensorineural/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Piebaldismo/complicaciones , Piebaldismo/fisiopatología , Reacción en Cadena de la Polimerasa/métodos , Gemelos/genética , Adulto Joven
7.
Medicina (Kaunas) ; 55(3)2019 Mar 25.
Artículo en Inglés | MEDLINE | ID: mdl-30934652

RESUMEN

The term congenital hypopigmentary disorders refers to a wide group of heterogeneous hereditary diseases, clinically characterized by inborn pigmentary defects of the iris, hair, and/or skin. They include Gray Hair Syndromes (GHSs), a rare group of autosomal recessive genodermatosis hallmarked by inborn silvery gray hair. GHSs encompass Griscelli, Chediak⁻Higashi, Elejalde, and Cross syndromes, which are all characterized by a broad spectrum of severe multisystem disorders, including neurological, ocular, skeletal, and immune system impairment. In this manuscript, we describe in detail the clinical, trichoscopic, and genetic features of a rare case of Griscelli syndrome; moreover, we provide an overview of all the GHSs known to date. Our report highlights how an accurate clinical examination with noninvasive methods, like trichoscopy, may play a crucial rule in diagnosis of rare and potentially lethal genetic syndromes such as Griscelli syndrome, in which timely diagnosis and therapy may modify the clinical course, quality of life, and likelihood of survival.


Asunto(s)
Trastornos de la Pigmentación/diagnóstico , Trastornos de la Pigmentación/genética , Enfermedades Raras/diagnóstico , Enfermedades Raras/genética , Anomalías Múltiples/diagnóstico , Anomalías Múltiples/genética , Anomalías Múltiples/inmunología , Anomalías Múltiples/patología , Adulto , Síndrome de Chediak-Higashi/diagnóstico , Síndrome de Chediak-Higashi/genética , Síndrome de Chediak-Higashi/inmunología , Síndrome de Chediak-Higashi/patología , Preescolar , Anomalías Craneofaciales/diagnóstico , Anomalías Craneofaciales/genética , Anomalías Craneofaciales/inmunología , Anomalías Craneofaciales/patología , Diagnóstico Diferencial , Femenino , Cabello/anomalías , Pérdida Auditiva Sensorineural/diagnóstico , Pérdida Auditiva Sensorineural/genética , Pérdida Auditiva Sensorineural/inmunología , Pérdida Auditiva Sensorineural/patología , Humanos , Hipertricosis/inducido químicamente , Iris/anomalías , Masculino , Mutación , Síndromes Neurocutáneos/diagnóstico , Síndromes Neurocutáneos/genética , Síndromes Neurocutáneos/inmunología , Síndromes Neurocutáneos/patología , Piebaldismo/diagnóstico , Piebaldismo/genética , Piebaldismo/inmunología , Piebaldismo/patología , Trastornos de la Pigmentación/inmunología , Trastornos de la Pigmentación/patología , Calidad de Vida , Enfermedades Raras/inmunología , Enfermedades Raras/patología , Anomalías Cutáneas , Proteínas rab27 de Unión a GTP/genética
8.
Arch Dermatol Res ; 310(10): 769-784, 2018 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-30218143

RESUMEN

Germline mutations on the CDKN2A gene, the most important known genetic factors associated with cutaneous melanomas (CMs), predispose carriers to multiple primary CMs (MPMs) with higher frequency and younger onset compared to non-carriers. Most of the largest published studies concerning clinical and histological characteristics of CMs with CDKN2A mutation carriers did not specify if the described CMs are first or subsequent to the first, and they used sporadic CMs from non-genotyped patients as controls. We conducted a single-centre observational study to compare clinical and histological CM features of 32 unrelated carriers (MUT) of 5 germline CDKN2A mutations (one of which was never previously described) compared to 100 genotyped wild-type (WT) patients. We stratified the data based on time of diagnosis, anatomical site and histological subtype of CMs, demonstrating several significant unreported differences between the two groups. MUT developed a higher number of dysplastic nevi and MPMs. We proved for the first time that anatomical distribution of CMs in MUT was independent of gender, unlike WTs. MUTs developed in situ and superficial spreading melanomas (SSMs) more frequently, with significantly higher number of SSMs on the head/neck. In MUTs, Breslow thickness was significantly lower for all invasive CMs. When CMs were stratified on the basis of the time of occurrence, statistical significance was maintained only for SSMs subsequent to the first. In WTs, Clark level was significantly higher, and ulceration was more prevalent than in MUTs. Significant differences in ulceration were observed only in SSMs. In nodular CMs, we did not find differences in terms of Breslow thickness or ulceration between WTs and MUTs. In situ CMs developed 10 years earlier in MUTs with respect to WTs, whereas no significant differences were observed in invasive CMs. In contrast to those reported previously by other authors, we did not find a difference in skin phototype.


Asunto(s)
Biomarcadores de Tumor/genética , Inhibidor p16 de la Quinasa Dependiente de Ciclina/genética , Mutación de Línea Germinal , Heterocigoto , Melanoma/genética , Neoplasias Cutáneas/genética , Adulto , Distribución por Edad , Estudios de Casos y Controles , Análisis Mutacional de ADN , Femenino , Predisposición Genética a la Enfermedad , Herencia , Humanos , Italia/epidemiología , Masculino , Melanoma/enzimología , Melanoma/etnología , Melanoma/patología , Persona de Mediana Edad , Linaje , Fenotipo , Factores de Riesgo , Distribución por Sexo , Neoplasias Cutáneas/enzimología , Neoplasias Cutáneas/etnología , Neoplasias Cutáneas/patología , Población Blanca/genética , Adulto Joven
12.
Anticancer Drugs ; 28(7): 808-810, 2017 08.
Artículo en Inglés | MEDLINE | ID: mdl-28489616

RESUMEN

The advent of immune checkpoint inhibitors anti-PD-1/PD-L1 has delivered new and effective treatment options with proven clinical benefits for patients affected by metastatic melanoma. The 30-40% of treated patients experience an objective tumour regression, with a significantly prolonged survival and an improved quality of life. Here, we report a case of a 75-year-old Caucasian woman affected by a massive cutaneous metastasis from a BRAF wild-type melanoma who experienced multiple relapses after surgery and repeated electrochemotherapy treatments. A poor response was observed after systemic therapy with ipilimumab, whereas a marked reduction in the lesion size was obtained during the treatment with nivolumab, with an objectively complete response after 6 months. Therapy was well tolerated, without immune-related side effects. During treatment, LDH levels decreased up to the standard values. Our experience confirms the good efficacy and the safety of anti-PD-1 nivolumab for the treatment of relapsed or refractory massive skin lesions, also in elderly patients.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Melanoma/tratamiento farmacológico , Neoplasias Cutáneas/tratamiento farmacológico , Factores de Edad , Anciano , Anticuerpos Monoclonales/efectos adversos , Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Femenino , Humanos , Melanoma/inmunología , Melanoma/patología , Nivolumab , Receptor de Muerte Celular Programada 1/antagonistas & inhibidores , Receptor de Muerte Celular Programada 1/inmunología , Neoplasias Cutáneas/inmunología , Neoplasias Cutáneas/secundario
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...